AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33109394
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation treatment + enhanced cue‐based treatment (interactive texting and cue management counseling)
Trial: 33109394
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation treatment + enhanced cue‐based treatment
Trial: 32062371
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hydrocortisone (LDH 10 mg)
Trial: 36224692
Drug: Norepinephrine 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.025 μg/(kg·min)
Trial: 36224692
Drug: Norepinephrine 0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.050 μg/(kg·min)
Trial: 36224692
Drug: Norepinephrine 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.075 μg/(kg·min)
Trial: 36224692
Drug: Norepinephrine 0.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.100 μg/(kg·min)
Trial: 36224692
Drug: Norepinephrine 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.125 μg/(kg·min)
Trial: 32584367
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) plus capecitabine (at phase 1 MTD of 700 mg/m2)
Trial: 34216466
Drug: Standard subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subcutaneous infiltration of dilute lidocaine solution
Trial: 32354366
Drug: Randomization to
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to low dose aspirin prior to pregnancy
Trial: 34372746
Drug: New prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prolonged-release leuprorelin acetate microspheres for injection (3.75 mg)
Trial: 34372746
Drug: Enantone® (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enantone® (3.75 mg)
Trial: 33052400
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous tropisetron before anesthesia induction
Trial: 32669121
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment using closed reduction and plaster immobilisation
Trial: 35690316
Drug: Phosphodiesterase‐5 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase‐5 inhibitors (PDE‐5i)
Trial: 33506054
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment for 2 weeks
Trial: 32857315
Drug: Ozanimod 0.46
RxNorm normalized name: ozanimod 0.46 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.46 mg (group A, n = 20)
Trial: 32857315
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily for 17 days + ozanimod 0.46 mg on day 4 (group B, n = 20)
Trial: 32857315
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg (group C, n = 20)
Trial: 32857315
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg once daily for 17 days + ozanimod 0.92 mg on day 4 (group D, n = 20)
Trial: 32857315
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for 21 days + ozanimod 0.92 mg on day 8 (group E, n = 20)
Trial: 32668845
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for childhood cancer, details on dosage and duration not available.
Trial: 33055544
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (mint-flavored sugar-free gum) for 20 minutes every 2 hours until colonoscopy after consuming 2 L of polyethylene glycol solution
Trial: 33055544
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol solution (control group)
Trial: 34779392
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive patch with newly sourced adhesive component at end of shelf life (EOSL)
Trial: 34779392
Drug: EVRA patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVRA patch at beginning of shelf life (BOSL)
Trial: 34309426
Drug: 0.18-mg fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18-mg fluocinolone acetonide insert
Trial: 35139273
Drug: Cemiplimab (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (350 mg every 3 weeks)
Trial: 35139273
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice of single-agent chemotherapy)
Trial: 36807215
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no laser treatment).
Trial: 35915917
Drug: Benson's Relaxation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's Relaxation, performed twice a day for 10 minutes for 8 weeks after a training session
Trial: 34415011
Drug: acceptance-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acceptance-based treatment (ABT)
Trial: 34375712
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) with imbedded 10 Hz binaural beats combined with standard treatment
Trial: 35331191
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT)-based self-help IMI
Trial: 34001070
Drug: Feeding volume
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding volume < 80 mL/kg/d at the end of the 4th week after birth
Trial: 34001070
Drug: Prolonged (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged (> 2 weeks) diuretics application
Trial: 35060026
Drug: Enhanced coagulation-flocculant
RxNorm normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced coagulation-flocculant process incorporating magnetic powder; 28.42 mg/L coagulant, 623 mg/L magnetic powder, 0.18 mg/L flocculant
Trial: 33289602
Drug: Sodium Hyaluronate/Chondroitin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Hyaluronate/Chondroitin Sulfate Preservative-free Ophthalmic Solution (SH/CS‐PF)
Trial: 36199177
Drug: Fenugreek seed
RxNorm normalized name: FENUGREEK SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek seed extract (5 cc) for 4 months
Trial: 34116144
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 10 mg/kg intravenously on days 1 and 8, every 21 days
Trial: 36427229
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO)
Trial: 33140886
Drug: Opioid receptor
RxNorm normalized name: Opioid receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid receptor antagonist naltrexone
Trial: 35441795
Drug: Tumescent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent solution with ropivacaine
Trial: 35441795
Drug: Tumescent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent solution without ropivacaine
Trial: 35441795
Drug: Tumescent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent solution with/without ropivacaine (inter-group comparison)
Trial: 33780271
Drug: 6-session solution-oriented
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-session solution-oriented goal-setting program
Trial: 32690072
Drug: Olanzapine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (starting dose 5 mg daily, maximum 20 mg daily)
Trial: 33588590
Drug: Intravenous Thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Thrombolysis (IVT)
Trial: 36163903
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg QD (PACE)
Trial: 36163903
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg QD (OPTIC)
Trial: 32524584
Drug: Early relapse
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early relapse after high-dose melphalan autologous stem cell transplant
Trial: 32524584
Drug: Later relapsing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later relapsing patients after high-dose melphalan autologous stem cell transplant
Trial: 33380392
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia (GA)
Trial: 33858190
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin plus standard chemotherapy (GO + SC)
Trial: 33858190
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy alone (SC)
Trial: 33786671
Drug: Experimental solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental solution (methylene blue dye with cetrimide) and aPDT
Trial: 33116410
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of valsartan 80 mg capsules under fasting conditions
Trial: 33116410
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of valsartan 80 mg capsules under fed conditions
Trial: 33116410
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of valsartan 80 mg capsules
Trial: 36165675
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day prednisolone for 2 years
Trial: 37164774
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) followed by curative chemo-radiotherapy (CTRT) or surgery and adjuvant (chemo)RT
Trial: 33620447
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment via smartphone application
Trial: 34780107
Drug: Longstanding active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longstanding active exercise therapy (52 weeks)
Trial: 35098177
Drug: ARCoV mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCoV mRNA vaccine (5 µg, 10 µg, 15 µg, 20 µg, 25 µg)
Trial: 35098177
Drug: ARCoV mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCoV mRNA vaccine
Trial: 35098177
Drug: ARCoV mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCoV mRNA vaccine (15 µg)
Trial: 34622504
Drug: 7-day vonoprazan-based
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 7-day vonoprazan-based triple therapy (7-VAC): vonoprazan 20 mg bid. pc., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Trial: 34622504
Drug: 14-day omeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day omeprazole-based triple therapy (14-OAC): omeprazole 20 mg bid. ac., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Trial: 34866250
Drug: Short Implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short Implants (SI)
Trial: 34866250
Drug: Standard Length
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Length Implants (SLI) with MSFA
Trial: 32173228
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education intervention consisting of oral presentation and distribution of fliers for 30 minutes.
Trial: 34154321
Drug: Neridronate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (25 mg i.m./month)
Trial: 35733086
Drug: Lidocaine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (4 ml of 2% lidocaine in the outer cuff)
Trial: 35733086
Drug: Remifentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (2 ng/ml maintained until extubation)
Trial: 33302570
Drug: 25‐hydroxyvitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐hydroxyvitamin D3 (25OHD) 10 µg per day for 16 weeks
Trial: 33653118
Drug: Ezogabine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezogabine (900 mg/day; N=21)
Trial: 33338441
Drug: SARS-CoV-2 antibody
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibody seropositivity in the general population
Trial: 33338441
Drug: SARS-CoV-2 antibody
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibody seropositivity in the high-risk population
Trial: 33073938
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg every night for three months
Trial: 35216750
Drug: Open-loop system
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop system (sensor-augmented pump therapy)
Trial: 32386001
Drug: Early goal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early goal directed sedation (EGDS) with continuous intravenous infusion of dexmedetomidine (initial dose of 0.2 μg×kg‐1×min‐1) for 72 hours
Trial: 32386001
Drug: Standard sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sedation (STD) with intravenous bolus of propofol
Trial: 32223108
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills (QLP), 6 g tid for 6 months
Trial: 32223108
Drug: Placebo control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control, 6 g tid for 6 months
Trial: 36458443
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T) of apixaban 2.5 mg under fasting conditions
Trial: 36458443
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (T) of apixaban 2.5 mg under fed conditions
Trial: 36458443
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (R) of apixaban 2.5 mg under fasting conditions
Trial: 36458443
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (R) of apixaban 2.5 mg under fed conditions
Trial: 34533034
Drug: Experimental strategy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental strategy: 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy
Trial: 34533034
Drug: Reference strategy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference strategy: 75 to 100 mg aspirin daily plus either 75 mg clopidogrel daily (for SCAD) or 90 mg ticagrelor twice daily (for ACS) for 12 months, followed by aspirin monotherapy for 12 months
Trial: 32513294
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg daily for 3 days, then tapered down over 6 weeks)
Trial: 32639465
Drug: Daptomycin (once-daily,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (once-daily, age-adjusted doses)
Trial: 34458925
Drug: 1% acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% acetaminophen gel
Trial: 34458925
Drug: 2.5% acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% acetaminophen gel
Trial: 34458925
Drug: 5% acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acetaminophen gel
Trial: 34455556
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg as needed (PRN) for patients with 2-8 MMD
Trial: 34455556
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg as needed (PRN) for patients with 9-14 MMD
Trial: 34455556
Drug: Rimegepant on
RxNorm normalized name: Rimegepant only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant on a fixed every-other-day schedule plus as needed dose (QOD+PRN) for patients with 4-14 MMD
Trial: 32255205
Drug: Ultrasound-guided betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided betamethasone injection with hydrodissection (5 mL)
Trial: 32255205
Drug: Ultrasound-guided betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided betamethasone injection without hydrodissection (2 mL)
Trial: 33812699
Drug: Ibuprofen (arginine)/tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (arginine)/tramadol 400/37.5 mg
Trial: 33812699
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg alone
Trial: 33812699
Drug: Ibuprofen arginine
RxNorm normalized name: ibuprofen arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen arginine 400 mg alone
Trial: 36243225
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (n = 124) with shockable rhythm
Trial: 36243225
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (n = 124) with non-shockable rhythm
Trial: 36243225
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 132) with shockable rhythm
Trial: 36243225
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 132) with non-shockable rhythm
Trial: 33929523
Drug: CMR (Comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMR (Comprehensive Medication Review)
Trial: 32466773
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg magnesium oxide plus 150 mg zinc sulfate for 12 weeks
Trial: 33536010
Drug: Ozone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (3 doses weekly)
Trial: 33536010
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) (3 doses weekly)
Trial: 33536010
Drug: Platelet Rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Rich Plasma (PRP) (2 doses with 3 weeks interval)
Trial: 33536010
Drug: Plasma Rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Rich in Growth Factors (PRGF) (2 doses with 3 weeks interval)
Trial: 35133411
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and behavioral counseling
Trial: 34074584
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg−1.kg−1 body mass)
Trial: 38864155
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of β-lactam antibiotics
Trial: 38864155
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of β-lactam antibiotics
Trial: 34275099
Drug: Incretin-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incretin-based therapy (sitagliptin followed by liraglutide)
Trial: 34472504
Drug: Arterolane maleate
RxNorm normalized name: maleate
DrugBank: Arterolane (DB19027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg
Trial: 33070154
Drug: JNJ‐42165279 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐42165279 (25 mg daily)
Trial: 33162202
Drug: Oral pentavalent
RxNorm normalized name: rotavirus vacc, live oral pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pentavalent rotavirus vaccine
Trial: 33727659
Drug: 0.1% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bromfenac sodium ophthalmic solution